← back to search

Ruoran Li

Yunnan University · GB
Area of research
Oncology · Modeling and Simulation
Research interest
Research interests include COVID-19 epidemiological studies, Tuberculosis Research and Epidemiology, COVID-19 and Mental Health, and Global Cancer Incidence and Screening.
h-index
17
citations
4,727
works
58
NIH funding
primary concept
Medicine
email

Recent publications

The effect of human mobility and control measures on the COVID-19 epidemic in China
Science 2020cited by 3,076position: middledoi
Estimated Demand for US Hospital Inpatient and Intensive Care Unit Beds for Patients With COVID-19 Based on Comparisons With Wuhan and Guangzhou, China
JAMA Network Open 2020cited by 125position: firstdoi
US-county level variation in intersecting individual, household and community characteristics relevant to COVID-19 and planning an equitable response: a cross-sectional analysis
BMJ Open 2020cited by 74position: middledoi
Human papillomavirus vaccine approval in China: a major step forward but challenges ahead
The Lancet Infectious Diseases 2016cited by 59position: middledoi
How much do tumor stage and treatment explain socioeconomic inequalities in breast cancer survival? Applying causal mediation analysis to population-based data
European Journal of Epidemiology 2016cited by 45position: firstdoi
Cancer survival differences between South Asians and non-South Asians of England in 1986–2004, accounting for age at diagnosis and deprivation
British Journal of Cancer 2015cited by 30position: middledoi
Control of data quality for population-based cancer survival analysis
Cancer Epidemiology 2014cited by 27position: firstdoi
Cancer burden in China and the role of the cancer registries.
PubMed 2014cited by 6position: firstdoi
Long-term trends in incidence, survival and mortality of primary penile cancer in England
Cancer Causes & Control 2013cited by 116position: middledoi
How much of socioeconomic differences in survival in patients with breast cancer can be explained by differences in stage of diagnosis and treatment? Application of causal mediation analysis to routine data
The Lancet 2013cited by 3position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Bernard Rachet · Toronto Western Hospital4 papers (2013–2016)Michel P. Coleman · University of London3 papers (2013–2015)Rhian Daniel · London School of Hygiene & Tropical Medicine2 papers (2013–2016)Laura M. Woods · London School of Hygiene & Tropical Medicine1 papers (2014–2014)William P. Hanage · Harvard University1 papers (2020–2020)Xiong‐Fei Pan · UNSW Sydney1 papers (2016–2016)Chia-Hung Yang · GenMont Biotech (Taiwan)1 papers (2020–2020)Christopher Dye · University of Oxford1 papers (2020–2020) · 1 papers (2020–2020)Alessandro Vespignani · Northeastern University1 papers (2020–2020)Rebecca Kahn · Centers for Disease Control and Prevention1 papers (2020–2020)Qi Tan · Nanjing Tech University1 papers (2020–2020)Punam Mangtani · London School of Hygiene & Tropical Medicine1 papers (2015–2015)Vijay Sangar · University of Manchester1 papers (2013–2013) · 1 papers (2020–2020)David M. Pigott · University of Washington1 papers (2020–2020)Mathew V. Kiang · Stanford Health Care1 papers (2020–2020)Oliver G. Pybus · Royal Veterinary College1 papers (2020–2020)Jonathan D. Moore · Campbellsville University1 papers (2014–2014)Huaiyu Tian · Beijing Normal University1 papers (2020–2020)